Mercer Global Advisors Inc. ADV Sells 921 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mercer Global Advisors Inc. ADV decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,179 shares of the specialty pharmaceutical company’s stock after selling 921 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Supernus Pharmaceuticals were worth $368,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $52,000. Headlands Technologies LLC grew its stake in shares of Supernus Pharmaceuticals by 203.0% in the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $72,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $92,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. StockNews.com downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $31.54 on Thursday. The company’s 50-day moving average is $31.86 and its 200 day moving average is $34.85. The company has a market capitalization of $1.77 billion, a P/E ratio of 29.48 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.